The phase 2 study primarily looked at safety. There was no correction for multiple hypothesis testing on the efficacy endpoints. So it seems that the only conclusion that is warranted is that the study shows no adverse health effects and that "larger clinical trials are warranted to establish the efficacy of hMSCs in this multisystem disorder." as they state in the conclusion.
It is interesting if it works, but lets wait for the next phase before assuming it does.
It is interesting if it works, but lets wait for the next phase before assuming it does.